- Resource
- BR1DGE
- Early Detection
- Video
The Evolving Landscape of Early Detection in T1D
Leading T1D experts discuss scaling up screening programs to support equitable access to early T1D detection, monitoring, and disease-modifying therapies.
Learning Objectives
- Explore the growing momentum behind early T1D detection across countries and communities
- Recognize how the emerging international consensus provides a framework for developing early detection pathways
Summary
This video explores the growing evidence for routine islet autoantibody screening and the evolving landscape of early detection in type 1 diabetes (T1D). Jaivir Pall describes increasing awareness of screening and early-stage T1D among patient advocacy groups across regions. Prof Anette-Gabriele Ziegler explains why equitable access requires moving beyond family history alone, and discusses how structured programs, central laboratories, and combined autoimmune screening panels can support embedding T1D screening into routine workflows. Prof Chantal Mathieu highlights how existing screening programs can act as a model for clinicians to build their own early T1D detection pathways.
MAT-GLB-2601299 - 1.0 - 08/2026
Faculty Disclosures
Jaivir Pall
- Speaker/Consultant: Sanofi, AbbVie
- Other: Eli Lilly and Company, Novo Nordisk, Dexcom, Minimed, Boehringer Ingelheim, Roche, Zubi Capital Diabetes-Immune, Fund I, Abvance Therapeutics, Ancilia Biosciences, Viven Therapeutics, Zya Enzymes, Zubi Group, Luna Life Limited, Unison Bio, BioSapien and Harbr Ventures Fund
Prof Anette-Gabriele Ziegler
- Speaker/Consultant: The Leona M. and Harry B. Helmsley Charitable Trust, Sanofi France
- Other: Received honoraria from Georg Thieme Verlag, Novo Nordisk Norway, and Deutsche Diabetes Gesellschaft; support for attending meetings from Sanofi France; member of data monitoring committees for Provention Bio, Sanofi, Sanofi US Services, and ITB-Med; advisory board member for Sanofi France and Sanofi-Aventis US
Prof Chantal Mathieu
- Research funding: Medtronic, Imcyse, Novo Nordisk, Sanofi, and ActoBio Therapeutics
- Speaker/Consultant: Sanofi
- Other: Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Boehringer Ingelheim, Roche, Medtronic, Imcyse, Insulet, Biomea Fusion, and Vertex
Communicating the Benefits of T1D Screening and Early Detection
Experts discuss how to effectively communicate the value of T1D screening and early detection to families, clinicians, and healthcare decision-makers.
Identifying Adult-onset T1D
Leading T1D experts explore how to distinguish adult-onset T1D from T2D and when to consider islet autoantibody testing in adults.
Advancing Models of Care for People with Type 1 Diabetes
Leading T1D experts discuss supportive care pathways, psychosocial support, and new models of care for people at risk of, or diagnosed with, type 1 diabetes.